FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD


January 11, 2018

In This Article

Rhopressa (netarsudil ophthalmic)


Reduction of elevated intraocular pressure (IOP) caused by open-angle glaucoma or ocular hypertension.


Rho kinase and norepinephrine transport inhibitor. Lowers IOP by increasing trabecular outflow.


Instill 1 drop (0.02% ophthalmic solution) in affected eye(s) once daily in evening.


Approval was based on two phase 3 clinical trials (Rocket 1 and Rocket 2) that enrolled 1,167 patients. Patients were randomized to receive netarsudil once daily (Rocket 1 or Rocket 2) or BID (Rocket 2 only). Timolol was dosed BID in both studies. Treatment with netarsudil once daily produced clinically and statistically significant reductions of IOP from baseline (P<0.001) and was noninferior to timolol in the per-protocol population, with maximum baseline IOP <25 mm Hg in both studies.


Serle JB, et al. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2017 Nov 30.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.